(Q46982269)

27 December 2017

title

6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension (English)

1 reference

27 December 2017

Nodular regenerative hyperplasia

0 references

1 reference

1 reference

based on heuristic

inferred from title

inflammatory bowel diseases

1 reference

based on heuristic

inferred from title

author

Markus Peck-Radosavljevic

8

1 reference

27 December 2017

Walter Reinisch

3

object named as

Walter Reinisch

1 reference

27 December 2017

author name string

Arnulf Ferlitsch

1

1 reference

27 December 2017

Alexander Teml

2

1 reference

27 December 2017

Gregor Ulbrich

4

1 reference

27 December 2017

Fritz Wrba

5

1 reference

27 December 2017

Monika Homoncik

6

1 reference

27 December 2017

Alfred Gangl

7

1 reference

27 December 2017

Harald Vogelsang

9

1 reference

27 December 2017

language of work or name

English

0 references

publication date

25 September 2007

1 reference

27 December 2017

The American Journal of Gastroenterology

published in

1 reference

27 December 2017

volume

102

1 reference

27 December 2017

issue

11

1 reference

27 December 2017

page(s)

2495-2503

1 reference

27 December 2017

Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Remission maintenance by tioguanine in chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

High variation of tioguanine absorption in patients with chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

6-thioguanine: a new old drug to procure remission in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Nodular regenerative hyperplasia (NRH) of the liver--a manifestation of 'organ-specific antiphospholipid syndrome'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Austrian consensus on the definition and treatment of portal hypertension and its complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

Prevention of variceal rebleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01530.X

10.1111/J.1572-0241.2007.01530.X

21 January 2018

Identifiers

DOI

1 reference

27 December 2017

1 reference

27 December 2017